Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think about $40 would be reasonable. This comes from an EBITDA of $125,000,000 and a multiple of 20. These numbers are from Laughing Waters and they seem to make sense. I don't see a buyout any time soon at anywhere near this SP. I may be naive but I think they had some more business lined up before the expansion that may have been delayed for some reason. It happens.
Not sure if this has been posted. From Laughing Water
"Starting with the recent positive industry developments, in early February it was announced that Novo Holdings would be purchasing Catalent Inc. (CTLT), a publicly traded CDMO, for $16.5B. Novo Holdings would then sell three fill-finish sites to Novo Nordisk for $11 billion. The fill-finish assets are the real prize here, as Novo Nordisk is the manufacturer of blockbuster weight loss drugs Ozempic and Wegovy, and there simply is not enough global fill-finish capacity to meet the demand for these drugs.
This transaction also has the potential to be hugely positive for Avid Bioservices, but in a different way. Avid’s largest customer is Halozyme Therapeutics, Inc. (NASDAQ:HALO), who has traditionally split their business between Avid and Catalent. While this business is not likely to be forced to leave the Novo-Catalent facilities as is the case with the fill-finish business, Novo Holdings and Novo Nordisk are both involved with products that are seen as competition for HALO’s products, and industry whispers are that HALO is not pleased with the idea of outsourcing the production of their drug substance to their competition. As such, HALO may seek to take their business away from Novo-Catalent. HALO is thus presented with a choice. They can either a) choose a new CDMO and go through an FDA review to move their production or b) they can move more production to Avid Bioservices, which would not require FDA approval. There are of course sole source risks to be considered, but it seems likely that Avid could pick up meaningful incremental business."
Yes indeed. Very excited about that third trial with 29 participants and an estimated trial completion date of March 2028.
Maybe it's time to give up on Bavi. It's been around for 20 years.
Sounds good. My point being if somebody allegedly sabotaged a multi-billion dollar drug phase 2 trial ten years ago and to date the drug has not earned a penny of revenue (other than being sold for $8m about 5 years ago) and hasn't sniffed a phase three, then maybe it isn't worth much.
Yes, I wonder what sales of Bavituximab would be this year if it weren't for JB n Fiken. In the hundreds of billions I bet. Funny stuff.
Crazy good call. I actually bought a little more last Thursday at 48. Wish I bought more than I did.
The end of this year seems early, but I would be ok with close to $30 pps. In a year and a half or so, assuming the expansion went as planned, I would be good with $40. Either way, I am concerned about missing out on the Bavi revenue. Just kidding.
Silly
Well said. Looking forward to how they finished up the year and guidance next week
I was pretty good in Economics. The $1,800 stimulus payments from the previous administration and the $1,400 stimulus payments from the current administration had some effect on inflation I suppose. Not nearly as much as the China shutdown, Ukraine war and bounce back from pandemic. I have a hard time tying those stimulus payments to the huge increase in gas prices and inflation in France, UK, Spain, Japan, Hong Kong, Australia, etc. Maybe it's supply and demand. Economics 101.
I was being facetious. One man isn't responsible for increased gas prices and inflation through out the whole world. I had hoped that would be obvious. Guess not.
Please explain why the value of our investments have dropped over the last few months. Does it have anything to do with the increase in gas prices and inflation world wide from coming out of the pandemic and the war in Ukraine? Let's see how this goes.
Thanks, you are probably correct, I would get something out of an ASM with this group as would most. I will say that grifters can be pretty convincing also. The last crew had many admirers. The group in there now are legit in my opinion.
I agree that there is little retail ownership here, but I would say it's in the 3%-5% range, 2-3m shares.
I don't see attendance at the ASM as a good barometer. If you're right on retail ownership then I own about 20% of total retail shares. I have never attended an ASM and never really considered going. I read and listen into everything that I believe matters. I never felt the need to look into the eyes of management as I don't believe it would help me personally on my investment. Touring the facility would be nice I guess but I'm certainly not qualified to know what I'm looking at.
The exact amount of retails shares doesn't really matter, but it is certainly low.
"We are down over 50% from highs"
Who is we? You can't possibly own this stock.
"It a POS, it's going to $3.00!" Two years later - "It's a POS it's going to $19+!" Hard to take serious.
Low teens? What happened to $3? Sounds like you're becoming a fan. Good to see.
"If what I hypothesize is correct, then the shares are changing hands to investors that have a higher cost basis which will make the next move up even better."
Exactly how I look at this right now.
Easy to say now. What was share price before all that?
Here’s my story with this stock. I bought at 15 and sold at 27 on the phase 3 results a short time later. Bought back more at about 16 and am currently way down with those.
Im not sure what you would have wanted to have happened, even in hindsight. Should they have not done the Covid trial? Not applied for EAU? Not produced any product? We’d have more cash if we did none of those but what would the share price be now? The same as before those events? Hard to say.
I disagree with your premise that the share price would be $6 as opposed to $4 if Dale didn’t sell at $16-$18, if that’s what you’re most angry about.
From what I can see, Dale is down well over $100m dollars from the FDA denial. You’d think he would have sold more knowing the FDAs decision and n advance. Could be that he had a few hundred million in one stock with a binary event approaching and he sold a minority of his shares. Just kidding.
Why can one continually accuse insiders (multiple) of a felony, but I can't question that? Odd.
To be clear, when you say management, you mean one person in management.
Funny stuff.
Yeah, what do you think the current share price would be if Dale didn’t sell a portion of his shares over the summer? 20? 30? More?
How many insiders sold?
So what you are saying is that one and only one insider knew three months in advance that the FDA was going to deny the EUA and sold some but not a majority of his shares that he indicated he was going to sell three months prior to that? I guess that makes sense.
I finally sold some as well. Sold 5k shares on Thursday at 33. Still holding almost 30 k accumulated over the past 15+ years. I think we could be at 40-50 in a year to a year and a half if all goes according to plan. Increased a position I had in another stock on Thursday with the proceeds and it went up 10% yesterday so it’s working out so far. A buyout down the road for CDMO would be nice because selling any of it for me is a tough decision.
I'm curious as to your reasoning behind this prediction. That's a lot of money. If it's for additional expansion I'd be concerned with how fast they are moving.
Finally got into this yesterday. Good timing.
Not 100% sure what you mean. If they execute their plan in the next year or two (finish the expansion and fill capacity without any major hiccups), they should be at $35-$40 with a possible buyout maybe $50+. That's all I was saying.
Well said. Agree with all, now they just need to execute.
“EUA assessment letter”? Is that what they are calling the FDA rejection letter or is that referring to something else?
Why? CDMO didn’t increase guidance. I’d take it though.
I agree with what you say and the reasons for the decline. It was a good quarter, not a great quarter. I'm not so sure they really blew away revenues or margins without factoring in that $3.1m payment for not using the space. Their margins with that were 37% and without it the margins were 28%. Good, not great.
Also, conservatively(I hope) left full year revenue estimates where they were.
Good quarter but I don't see any price target upgrades from it. Hope I'm wrong.
You're going to sell if there is no EUA this week although you think HGEN will be bought out within six months or so for about triple what you will sell out for? Let us know what you are going to use the proceeds for that you think will be better than a six month triple.
My very rudimentary understanding is that Lenz doesn't attack the virus, it works to limit the reactions to the virus in some patients (Cytokine storm). Variants should not matter.
Are you still optimistic on the EUA? I'm losing a little faith. From 90-10 for to about 50-50 now. It seemed like a no brainer at one point but maybe not enough patients in the trial or history with the drug. Taking an awful long time.
Thanks on this one Vinmantoo. Got in on your recommendation and averaged down to $7.50.
Thank you Vinmantoo for TRIL.